TaBlitz, St. Louis, MO (2026)

04/13/2026

𝐉𝐨𝐢𝐧 𝐃𝐫. 𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐋𝐢𝐯𝐞 𝐓𝐨𝐦𝐨𝐨𝐫𝐫𝐨𝐰!

Every month, we take one real formulation or production problem—sticking, picking, capping, lamination, scale-up breakdowns—and open it up.

𝘙𝘦𝘢𝘭 𝘧𝘰𝘰𝘵𝘢𝘨𝘦. 𝘙𝘦𝘢𝘭 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴. 𝘙𝘦𝘢𝘭 𝘢𝘯𝘴𝘸𝘦𝘳𝘴.

You’ll see what’s happening inside and outside the tablet press during compaction.
You’ll watch live TaBlitz demos tracing root cause in real time.
And you’ll hear expert insight connecting what’s happening on press to why it’s happening in your formulation.

We close every session with live Q&A—bring the question that’s been holding your batch back and get a direct answer.

🚨 1 day away — don’t miss it

Join Pharma Excipients, all4nutra.com, Dr. TaBlitz, and Natoli Scientific

𝗗𝗿. 𝗧𝗮𝗯𝗹𝗶𝘁𝘇 𝗟𝗶𝘃𝗲 𝗦𝗲𝘀𝘀𝗶𝗼𝗻𝘀
📅 Tuesday, Apr. 14, 2026
⏰ 10:00 AM EDT | 4:00 PM CET

Streaming live on YouTube and LinkedIn.

👉 Set your reminder and subscribe so you don’t miss it:
https://lnkd.in/erQGPcQH

03/03/2026

𝐈𝐟 𝐲𝐨𝐮’𝐫𝐞 𝐚 𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐃𝐫𝐮𝐠 𝐂𝐨𝐦𝐩𝐚𝐧𝐲, 𝐭𝐡𝐢𝐬 𝐜𝐚𝐫𝐨𝐮𝐬𝐞𝐥 𝐢𝐬 𝐫𝐞𝐪𝐮𝐢𝐫𝐞𝐝 𝐫𝐞𝐚𝐝𝐢𝐧𝐠.

Because this is exactly where TaBlitz fits — and why it matters.

Here’s the uncomfortable truth:

When you operate asset-light, your leverage doesn’t come from equipment.
It comes from insight.
If you're building a program without owning manufacturing, let’s talk about how to own the risk instead.

Reserve a 1-hour session and explore how predictive insight can save time, material, and cost.
The link: https://lnkd.in/gA2SrvjS

02/26/2026

𝐀 𝐒𝐮𝐩𝐩𝐨𝐫𝐭 𝐓𝐨𝐨𝐥. 𝐍𝐨𝐭 𝐚 𝐑𝐞𝐩𝐥𝐚𝐜𝐞𝐦𝐞𝐧𝐭.

It’s worth repeating:

TaBlitz does not replace experimental validation.
It does not replace formulator judgment.
It does not replace regulatory requirements.

What it does is guide early decisions — so your experimental effort is focused where it’s most likely to succeed.

For formulation scientists who have spent years mastering the art and science of DoE, this isn’t disruption. It’s refinement.

Think of it this way:

• DoE is the expedition.
• You still climb the mountain.
• You still collect the data.
• You still prove the robustness.

TaBlitz simply gives you an accurate topographic map before you begin — so you start in the right mountain range instead of wandering through barren territory.

𝐓𝐡𝐞 𝐞𝐱𝐩𝐞𝐫𝐢𝐦𝐞𝐧𝐭 𝐬𝐭𝐢𝐥𝐥 𝐛𝐞𝐥𝐨𝐧𝐠𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭.

𝐖𝐞 𝐣𝐮𝐬𝐭 𝐡𝐞𝐥𝐩 𝐞𝐧𝐬𝐮𝐫𝐞 𝐭𝐡𝐞 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐬𝐭𝐚𝐫𝐭𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐩𝐥𝐚𝐜𝐞.

Book your demo today: https://lnkd.in/gA2SrvjS

02/24/2026

𝐁𝐫𝐢𝐧𝐠𝐢𝐧𝐠 𝐐𝐛𝐃 𝐚𝐧𝐝 𝐃𝐨𝐄 𝐈𝐧𝐭𝐨 𝐭𝐡𝐞 𝐌𝐢𝐱

This is where Quality by Design (QbD) truly earns its place in modern development.

Instead of reacting to problems at scale, you proactively map your critical material attributes early — flowability, compressibility, cohesion — and connect them directly to tablet quality targets like tensile strength, friability, and dissolution performance.

You move from trial-and-error to structured understanding.

But let’s be honest.

Design of Experiments (DoE) is powerful — especially for uncovering interactions.

The challenge? Broad experimental ranges often consume time, material, and effort exploring dead zones that were never viable to begin with.

𝐒𝐨 𝐭𝐡𝐞 𝐫𝐞𝐚𝐥 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧 𝐛𝐞𝐜𝐨𝐦𝐞𝐬:

What if you could narrow the field before you ever press “run”?

If you're looking to reduce downstream risk and build from physics, not assumptions, let’s connect.

Book your demo today: https://lnkd.in/gHQCv72d

02/13/2026

𝐕𝐢𝐫𝐭𝐮𝐚𝐥 𝐃𝐫𝐮𝐠 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐚𝐫𝐞 𝐛𝐮𝐢𝐥𝐭 𝐭𝐨 𝐨𝐩𝐞𝐫𝐚𝐭𝐞 𝐥𝐞𝐚𝐧.
But lean should never mean blind.

When you don’t own manufacturing, your leverage comes from clarity.

Clarity on your formulation.
Clarity on your risks.
Clarity on what will — and won’t — scale.

That’s where TaBlitz changes the equation.

We help VDCs move forward with:

✅ Early, material-sparing insight
✅ Physics-based formulation confidence
✅ Predictive robustness before scale-up
✅ A stronger technical position with CDMOs
✅ A cleaner, more defensible narrative for regulators and investors

This isn’t incremental value.

It’s structural risk reduction.

If you’re building lean, build informed.

Let’s talk. Demo here: https://lnkd.in/gHQCv72d

02/12/2026

𝐌𝐨𝐬𝐭 𝐭𝐚𝐛𝐥𝐞𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞𝐬 𝐚𝐫𝐞𝐧’𝐭 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭.
𝐓𝐡𝐞𝐲’𝐫𝐞 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐚𝐭 𝐭𝐡𝐞 𝐰𝐨𝐫𝐬𝐭 𝐩𝐨𝐬𝐬𝐢𝐛𝐥𝐞 𝐦𝐨𝐦𝐞𝐧𝐭.

Traditionally, failure modes show up in one of three painful ways:

🔹 During the first engineering or exhibit batch — when confidence is high and timelines are tight.
🔹 During PPQ — the most expensive moment to learn something new about your formulation.
🔹 After approval — when a new raw material lot or seasonal humidity shift quietly pushes the process outside its undocumented limits.

By the time these issues appear, the formulation is locked, the validation plan is active, and the cost of adjustment is measured in weeks — not hours.

𝐖𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 𝐭𝐡𝐢𝐬 𝐞𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐥𝐲 𝐟𝐫𝐮𝐬𝐭𝐫𝐚𝐭𝐢𝐧𝐠?

In most cases, the failure wasn’t random.
It was hiding in the physics — in the micromeritics, the compaction limits, the strain-rate sensitivity, the geometry stress distribution.

It just wasn’t evaluated early enough.

The strongest teams are no longer asking,
“Did it pass?”

They’re asking,
“Where are the edges — and have we tested them?”

Because robustness isn’t proven at the center of the design space.
It’s proven at the boundaries.

And discovering those boundaries during PPQ is not a strategy — it’s a gamble.

👉 If you want to identify your formulation’s edges before engineering batches, PPQ, or post-approval variability does it for you, let’s talk.
Schedule a demo and see how predictive robustness changes the way you approach scale-up.

Schedule your demo here: https://lnkd.in/gA2SrvjS

01/30/2026

Have you ever designed a tablet that worked perfectly on paper…
only to realize it physically couldn’t be made?

The formulation was sound.
The was in spec.
Early looked promising.

Then someone asked the question that stops projects cold:

“Will this actually fit into the tablet we’re trying to make?”

That’s when bulk density quietly takes control.

𝐖𝐡𝐲 𝐁𝐮𝐥𝐤 𝐃𝐞𝐧𝐬𝐢𝐭𝐲 𝐢𝐬 𝐊𝐞𝐲 𝐭𝐨 𝐘𝐨𝐮𝐫 𝐎𝐮𝐭𝐜𝐨𝐦𝐞

In tablet design, bulk density determines how much mass can physically enter the die before compression even begins.

When bulk density is too low:

✅ You can’t hit target tablet weight
✅ Tablet size reductions become impossible
✅ Fill depth maxes out early
✅ Scale-up flexibility disappears

And once you reach manufacturing, the formulation is locked. There’s no easy fix.

𝐖𝐡𝐲 𝐓𝐞𝐚𝐦𝐬 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐓𝐡𝐢𝐬 𝐓𝐨𝐨 𝐋𝐚𝐭𝐞

Most formulation teams don’t encounter bulk density limits until:

✅ A tablet size reduction is requested
✅ Drug load increases
✅ A new excipient lot behaves slightly differently
✅ Scale-up introduces tighter geometric constraints

At that point, the question shifts from “Is this optimal?” to
“How do we salvage this?”

That’s an expensive pivot.

𝐇𝐨𝐰 𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐂𝐡𝐚𝐧𝐠𝐞𝐬 𝐭𝐡𝐞 𝐂𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧

TaBlitz doesn’t treat bulk density as a background data point.

It treats it as a .

By combining bulk density with:

✅ Tablet geometry
✅ Target tablet weight
✅ Tooling design
✅ Compression limits

TaBlitz answers a question most teams only ask after problems appear:

“𝐈𝐬 𝐭𝐡𝐢𝐬 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐩𝐡𝐲𝐬𝐢𝐜𝐚𝐥𝐥𝐲 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐚𝐛𝐥𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐭𝐚𝐛𝐥𝐞𝐭 𝐰𝐞 𝐰𝐚𝐧𝐭?”

Before you:

✅ Run a
✅ Consume kilos of API
✅ Redesign tooling
✅ Hit a scale-up wall

A Scenario We See All the Time

A team designs a 500 mg tablet early on. Everything works.

Later, the request comes in:

👉 Increase drug load
👉 Reduce tablet size
👉 Improve swallowability

On paper, it looks achievable.

𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐟𝐥𝐚𝐠𝐬 𝐭𝐡𝐞 𝐢𝐬𝐬𝐮𝐞 𝐢𝐧𝐬𝐭𝐚𝐧𝐭𝐥𝐲:

At this , the cannot physically fit into the proposed tablet geometry.

Not maybe.
Not let’s try.
Cannot.

That insight alone can save months of reformulation.

𝐖𝐡𝐲 𝐓𝐡𝐢𝐬 𝐌𝐚𝐭𝐭𝐞𝐫𝐬 𝐭𝐨 #𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭𝐬

Bulk density doesn’t just affect filling.

It defines:

✅ Design flexibility
✅ Late-stage change options
✅ Scale-up success
✅ Project momentum

TaBlitz helps teams move from:

➡️ Trial-and-error
➡️ Firefighting

to:

➡️ Predictive design
➡️ Confident decision-making

𝐈𝐟 𝐲𝐨𝐮 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 𝐡𝐨𝐰 𝐛𝐮𝐥𝐤 𝐝𝐞𝐧𝐬𝐢𝐭𝐲 𝐢𝐬 𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐲𝐨𝐮𝐫 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 — 𝐛𝐞𝐟𝐨𝐫𝐞 𝐢𝐭 𝐥𝐢𝐦𝐢𝐭𝐬 𝐭𝐡𝐞𝐦 — 𝐬𝐜𝐡𝐞𝐝𝐮𝐥𝐞 𝐚 𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐝𝐞𝐦𝐨 𝐚𝐧𝐝 𝐬𝐞𝐞 𝐢𝐭 𝐩𝐫𝐞𝐝𝐢𝐜𝐭𝐞𝐝, 𝐧𝐨𝐭 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝 𝐭𝐡𝐞 𝐡𝐚𝐫𝐝 𝐰𝐚𝐲.

01/29/2026

𝐍𝐚𝐭𝐨𝐥𝐢 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐒𝐤𝐢𝐥𝐥 𝐁𝐮𝐢𝐥𝐝𝐞𝐫 𝐒𝐞𝐫𝐢𝐞𝐬

This isn’t a lecture.
It’s hands-on, press-side learning, working directly with experts to understand why these issues happen—and how to diagnose and prevent them using real compaction data and best practices aligned with modern tablet characterization.

If you’re responsible for making tablets work at speed, at scale, and under real constraints, there is no substitute for building that knowledge side by side with the experts.

👉 Watch the video. If these questions sound familiar, sign up for the Natoli Scientific Skill Builder Series and turn press-side problems into confident decisions.

Sign up here: https://lnkd.in/dPytE8yd

01/28/2026

𝐓𝐡𝐢𝐬 𝐜𝐨𝐮𝐥𝐝 𝐛𝐞 𝐨𝐮𝐫 𝐦𝐨𝐬𝐭 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐩𝐨𝐬𝐭 𝐲𝐞𝐭.

Most teams don’t struggle with Quality by Design because the framework is wrong.
They struggle because insight arrives after the cost has already been paid—
in kilograms of API, repeated DoE cycles, and late-stage rework.

This carousel walks through a familiar pattern:
• Where development costs quietly escalate
• Why material-heavy learning is often a symptom of late insight
• How integrating predictive understanding earlier changes both science and economics

If your QbD strategy is sound but development still feels expensive, this story is for you.

👉 𝘚𝘸𝘪𝘱𝘦 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘵𝘰 𝘴𝘦𝘦 𝘩𝘰𝘸 𝘵𝘦𝘢𝘮𝘴 𝘢𝘳𝘦 𝘳𝘦𝘥𝘶𝘤𝘪𝘯𝘨 𝘤𝘰𝘴𝘵 𝘣𝘺 𝘤𝘩𝘢𝘯𝘨𝘪𝘯𝘨 𝘸𝘩𝘦𝘯 𝘵𝘩𝘦𝘺 𝘭𝘦𝘢𝘳𝘯—𝘯𝘰𝘵 𝘩𝘰𝘸 𝘮𝘶𝘤𝘩 𝘵𝘩𝘦𝘺 𝘦𝘹𝘱𝘦𝘳𝘪𝘮𝘦𝘯𝘵.

𝐁𝐨𝐨𝐤 𝐭𝐡𝐞 𝐝𝐞𝐦𝐨 𝐡𝐞𝐫𝐞: https://lnkd.in/g5UgjDYv

01/22/2026

𝐎𝐧𝐞 𝐜𝐨𝐨𝐥 𝐟𝐚𝐜𝐭 𝐚𝐛𝐨𝐮𝐭 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐞-𝐫𝐞𝐚𝐝𝐲 𝐭𝐚𝐛𝐥𝐞𝐭 𝐞𝐦𝐛𝐨𝐬𝐬𝐢𝐧𝐠 (𝐭𝐡𝐚𝐭 𝐦𝐚𝐧𝐲 𝐭𝐞𝐚𝐦𝐬 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐭𝐨𝐨 𝐥𝐚𝐭𝐞):

Embossing isn’t just a branding decision—𝐢𝐭’𝐬 𝐚 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧.

Embossed tablets change how stress moves through the tablet during compression. The depth, geometry, and placement of an emboss can directly influence tensile strength, edge chipping, lamination risk, and even how a tablet behaves at higher press speeds.

This is where manufacture-ready embossing matters.

TaBlitz helps teams evaluate embossing choices before they become a press-side problem—by connecting material properties, compaction behavior, and tooling geometry into a single, predictive view. Instead of finding out during scale-up that an emboss weakens a tablet or narrows the operating window, teams can understand the risk earlier and design around it.

The result:

• Fewer late-stage tooling changes
• More robust tablets at production speeds
• Stronger confidence that what works in development will hold up in manufacturing

It’s a small design detail with a big impact—and one more example of how predictability is built, not discovered.

Book a demo to see the world's only unified OSD workflow software today: https://lnkd.in/g5UgjDYv

01/20/2026

𝐀 𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐝𝐞𝐦𝐨 𝐢𝐬𝐧’𝐭 𝐚𝐛𝐨𝐮𝐭 𝐬𝐞𝐞𝐢𝐧𝐠 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞.
It’s about seeing your entire OSD workflow clearly—from start to finish.

From early material understanding, through formulation and compaction, to robust gates, scale-up, and manufacturing continuity—TaBlitz supports OSD development as a single, connected workflow.

𝐖𝐡𝐚𝐭 𝐭𝐞𝐚𝐦𝐬 𝐬𝐞𝐞 𝐢𝐧 𝐚 𝐝𝐞𝐦𝐨:

• How material properties translate into compaction behavior
• How to identify manufacturability risk before scale-up
• How to build robust, data-backed decision gates
• How Model-Informed Drug Development (MIDD) works in practice—not theory
• How reporting stays consistent across teams, CMOs, and programs

For , this means clearer gates, stronger partner alignment, and more confident investor and regulator conversations.
For pharma teams, it means fewer surprises, less rework, and better decisions earlier.

The outcome isn’t more data.
It’s predictability by design.

If improving confidence, efficiency, and continuity across your OSD programs is a priority, the best next step is simple:

👉𝐁𝐨𝐨𝐤 𝐚 𝐓𝐚𝐁𝐥𝐢𝐭𝐳 𝐝𝐞𝐦𝐨 𝐚𝐧𝐝 𝐬𝐞𝐞 𝐰𝐡𝐚𝐭 𝐞𝐧𝐝-𝐭𝐨-𝐞𝐧𝐝, 𝐝𝐚𝐭𝐚-𝐝𝐫𝐢𝐯𝐞𝐧 𝐭𝐚𝐛𝐥𝐞𝐭 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐥𝐨𝐨𝐤𝐬 𝐥𝐢𝐤𝐞: https://lnkd.in/g5UgjDYv

TaBlitz

04/13/2026

03/03/2026

02/26/2026

02/24/2026

02/13/2026

02/12/2026

01/30/2026

01/29/2026

01/28/2026

01/22/2026

01/20/2026

Address

Website

Alerts

Contact The Business

Shortcuts

Share

Category